There are 2867 resources available
677P - A phase I study of the CDK4/6 inhibitor, palbociclib in combination with cetuximab and intensity modulated radiation therapy (IMRT) for locally advanced squamous cell carcinoma of the head and neck (SCCHN): An expansion cohort
Presenter: Nuttapong Ngamphaiboon
Session: Poster session 10
678P - Real-world evidence of first-line cetuximab (CX) plus paclitaxel (PX) in recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN)
Presenter: Beatriz Cirauqui Cirauqui
Session: Poster session 10
679P - Clinical outcomes in patients with recurrent or metastatic head and neck squamous cell carcinoma after failure of platinum and nivolumab: A multicenter retrospective study
Presenter: Hiroki Oka
Session: Poster session 10
680P - HANNA: Real-world data of patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN), including first-line population, treated with nivolumab in Germany
Presenter: Christiane Langer
Session: Poster session 10
681P - OPTIM: A randomized phase II study on the OPTimization of IMmunotherapy in squamous carcinoma of the head and neck – AIO-KHT-0117
Presenter: Viktor Gruenwald
Session: Poster session 10
682P - Patient characteristics and treatment patterns of newly diagnosed locally advanced head and neck squamous cell carcinoma (LA HNSCC): A retrospective cohort analysis of real-world data in England
Presenter: Anthony Kong
Session: Poster session 10
683P - Pembrolizumab plus nabpaclitaxe and platinum as first-line treatment in patients with recurrent or metastatic head and neck squamous-cell carcinoma: A prospective phase II study
Presenter: Lin Gui
Session: Poster session 10
684P - Liquid biopsy for detection of molecular residual disease and recurrence in head and neck squamous cell carcinoma
Presenter: Susanne Flach
Session: Poster session 10
685P - Genomic characteristics and immunotherapy outcomes in patients with recurrent/metastatic head and neck squamous cell carcinoma (HNSCC)
Presenter: Jong Chul Park
Session: Poster session 10
686P - Next generation sequencing (NGS) helps predict response to immunotherapy (IO) in recurrent or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) patients (pts)
Presenter: Oriol Mirallas
Session: Poster session 10